213 related articles for article (PubMed ID: 26883703)
1. Pharmacokinetics and Concentration-Dependent Efficacy of Isavuconazole for Treatment of Experimental Invasive Pulmonary Aspergillosis.
Petraitis V; Petraitiene R; Moradi PW; Strauss GE; Katragkou A; Kovanda LL; Hope WW; Walsh TJ
Antimicrob Agents Chemother; 2016 May; 60(5):2718-26. PubMed ID: 26883703
[TBL] [Abstract][Full Text] [Related]
2. Combination Therapy with Isavuconazole and Micafungin for Treatment of Experimental Invasive Pulmonary Aspergillosis.
Petraitis V; Petraitiene R; McCarthy MW; Kovanda LL; Zaw MH; Hussain K; Shaikh N; Maung BBW; Sekhon NK; Hope WW; Walsh TJ
Antimicrob Agents Chemother; 2017 Sep; 61(9):. PubMed ID: 28696236
[TBL] [Abstract][Full Text] [Related]
3. Combination Therapy with Ibrexafungerp (Formerly SCY-078), a First-in-Class Triterpenoid Inhibitor of (1→3)-β-d-Glucan Synthesis, and Isavuconazole for Treatment of Experimental Invasive Pulmonary Aspergillosis.
Petraitis V; Petraitiene R; Katragkou A; Maung BBW; Naing E; Kavaliauskas P; Barat S; Borroto-Esoda K; Azie N; Angulo D; Walsh TJ
Antimicrob Agents Chemother; 2020 May; 64(6):. PubMed ID: 32179521
[TBL] [Abstract][Full Text] [Related]
4. Antifungal activity and pharmacokinetics of posaconazole (SCH 56592) in treatment and prevention of experimental invasive pulmonary aspergillosis: correlation with galactomannan antigenemia.
Petraitiene R; Petraitis V; Groll AH; Sein T; Piscitelli S; Candelario M; Field-Ridley A; Avila N; Bacher J; Walsh TJ
Antimicrob Agents Chemother; 2001 Mar; 45(3):857-69. PubMed ID: 11181372
[TBL] [Abstract][Full Text] [Related]
5. Efficacy, safety, and plasma pharmacokinetics of escalating dosages of intravenously administered ravuconazole lysine phosphoester for treatment of experimental pulmonary aspergillosis in persistently neutropenic rabbits.
Petraitiene R; Petraitis V; Lyman CA; Groll AH; Mickiene D; Peter J; Bacher J; Roussillon K; Hemmings M; Armstrong D; Avila NA; Walsh TJ
Antimicrob Agents Chemother; 2004 Apr; 48(4):1188-96. PubMed ID: 15047519
[TBL] [Abstract][Full Text] [Related]
6. Pharmacodynamics of isavuconazole in experimental invasive pulmonary aspergillosis: implications for clinical breakpoints.
Kovanda LL; Petraitiene R; Petraitis V; Walsh TJ; Desai A; Bonate P; Hope WW
J Antimicrob Chemother; 2016 Jul; 71(7):1885-91. PubMed ID: 27084921
[TBL] [Abstract][Full Text] [Related]
7. Isavuconazole (BAL4815) pharmacodynamic target determination in an in vivo murine model of invasive pulmonary aspergillosis against wild-type and cyp51 mutant isolates of Aspergillus fumigatus.
Lepak AJ; Marchillo K; Vanhecker J; Andes DR
Antimicrob Agents Chemother; 2013 Dec; 57(12):6284-9. PubMed ID: 24100500
[TBL] [Abstract][Full Text] [Related]
8. Effects of host response and antifungal therapy on serum and BAL levels of galactomannan and (1→3)-β-D-glucan in experimental invasive pulmonary aspergillosis.
Petraitiene R; Petraitis V; Bacher JD; Finkelman MA; Walsh TJ
Med Mycol; 2015 Aug; 53(6):558-68. PubMed ID: 26129890
[TBL] [Abstract][Full Text] [Related]
9. Isavuconazole: A New Broad-Spectrum Triazole Antifungal Agent.
Miceli MH; Kauffman CA
Clin Infect Dis; 2015 Nov; 61(10):1558-65. PubMed ID: 26179012
[TBL] [Abstract][Full Text] [Related]
10. Pharmacodynamics of Isavuconazole in a Dynamic In Vitro Model of Invasive Pulmonary Aspergillosis.
Box H; Livermore J; Johnson A; McEntee L; Felton TW; Whalley S; Goodwin J; Hope WW
Antimicrob Agents Chemother; 2016 Jan; 60(1):278-87. PubMed ID: 26503648
[TBL] [Abstract][Full Text] [Related]
11. Pharmacodynamics of isavuconazole in an Aspergillus fumigatus mouse infection model.
Seyedmousavi S; Brüggemann RJ; Meis JF; Melchers WJ; Verweij PE; Mouton JW
Antimicrob Agents Chemother; 2015 May; 59(5):2855-66. PubMed ID: 25753636
[TBL] [Abstract][Full Text] [Related]
12. Pharmacodynamics of Isavuconazole for Invasive Mold Disease: Role of Galactomannan for Real-Time Monitoring of Therapeutic Response.
Kovanda LL; Kolamunnage-Dona R; Neely M; Maertens J; Lee M; Hope WW
Clin Infect Dis; 2017 Jun; 64(11):1557-1563. PubMed ID: 28472247
[TBL] [Abstract][Full Text] [Related]
13. Antifungal efficacy of caspofungin (MK-0991) in experimental pulmonary aspergillosis in persistently neutropenic rabbits: pharmacokinetics, drug disposition, and relationship to galactomannan antigenemia.
Petraitiene R; Petraitis V; Groll AH; Sein T; Schaufele RL; Francesconi A; Bacher J; Avila NA; Walsh TJ
Antimicrob Agents Chemother; 2002 Jan; 46(1):12-23. PubMed ID: 11751105
[TBL] [Abstract][Full Text] [Related]
14. Comparative antifungal activities and plasma pharmacokinetics of micafungin (FK463) against disseminated candidiasis and invasive pulmonary aspergillosis in persistently neutropenic rabbits.
Petraitis V; Petraitiene R; Groll AH; Roussillon K; Hemmings M; Lyman CA; Sein T; Bacher J; Bekersky I; Walsh TJ
Antimicrob Agents Chemother; 2002 Jun; 46(6):1857-69. PubMed ID: 12019101
[TBL] [Abstract][Full Text] [Related]
15. Population Pharmacokinetics of Isavuconazole from Phase 1 and Phase 3 (SECURE) Trials in Adults and Target Attainment in Patients with Invasive Infections Due to Aspergillus and Other Filamentous Fungi.
Desai A; Kovanda L; Kowalski D; Lu Q; Townsend R; Bonate PL
Antimicrob Agents Chemother; 2016 Sep; 60(9):5483-91. PubMed ID: 27381396
[TBL] [Abstract][Full Text] [Related]
16. The initial 96 hours of invasive pulmonary aspergillosis: histopathology, comparative kinetics of galactomannan and (1->3) β-d-glucan and consequences of delayed antifungal therapy.
Hope WW; Petraitis V; Petraitiene R; Aghamolla T; Bacher J; Walsh TJ
Antimicrob Agents Chemother; 2010 Nov; 54(11):4879-86. PubMed ID: 20713673
[TBL] [Abstract][Full Text] [Related]
17. Isavuconazole: A new broad-spectrum azole. Part 2: pharmacokinetics and clinical activity.
Ledoux MP; Denis J; Nivoix Y; Herbrecht R
J Mycol Med; 2018 Mar; 28(1):15-22. PubMed ID: 29551442
[TBL] [Abstract][Full Text] [Related]
18. Pharmacodynamics of the Orotomides against
Hope WW; McEntee L; Livermore J; Whalley S; Johnson A; Farrington N; Kolamunnage-Dona R; Schwartz J; Kennedy A; Law D; Birch M; Rex JH
mBio; 2017 Aug; 8(4):. PubMed ID: 28830945
[TBL] [Abstract][Full Text] [Related]
19. Exposure-Response Relationships for Isavuconazole in Patients with Invasive Aspergillosis and Other Filamentous Fungi.
Desai AV; Kovanda LL; Hope WW; Andes D; Mouton JW; Kowalski DL; Townsend RW; Mujais S; Bonate PL
Antimicrob Agents Chemother; 2017 Dec; 61(12):. PubMed ID: 28923872
[TBL] [Abstract][Full Text] [Related]
20. Impact of Mucositis on Absorption and Systemic Drug Exposure of Isavuconazole.
Kovanda LL; Marty FM; Maertens J; Desai AV; Lademacher C; Engelhardt M; Lu Q; Hope WW
Antimicrob Agents Chemother; 2017 Jun; 61(6):. PubMed ID: 28289034
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
